New study 80 of people with established cardiovascular disease significantly underuse statins

ST. PAUL Minn. July 21 2015 PRNewswire &160;The first of two cholesterollowering PCSK9 inhibitors Proprotein Convertase SubtilisinKexin type 9 is expected to be approved by the U.S. Food and Drug Administration FDA as early as this week. To guide...